Post
ESCMID 2024: Using AI in infection prevention and control
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
Pioneer Institute study finds IRA discourages non-opioid drug innovation
A study from a US-based public policy research firm has highlighted that the US Inflation Reduction Act (IRA) is likely …
The privileged status of orphan medicines in Germany
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question …
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, …
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead …
Merck’s net income for Q1 2024 increases by 69% to $4.76bn
Merck & Co Inc (MSD) has reported a significant increase in net income attributable to shareholders, reaching $4.76bn in the …
Multiply Labs and GenScript partner on cell isolation automation
Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in …
Regeneron and Mammoth team up to develop gene editing therapies
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing …
AstraZeneca posts $2.18bn profit after tax in Q1 2024
AstraZeneca has reported profit after tax of $2.18bn for the first quarter (Q1) of 2024, a notable rise from $1.80bn …
Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovy
Senator Bernie Sanders has targeted the high drug prices of Novo Nordisk’s Ozempic and Wegovy, revealing that the Senate Committee …
Cidara buys back rights to flu therapy from J&J for $85m
Cidara Therapeutics has entered into a definitive agreement with Johnson & Johnson (J&) to buy back the rights to its …
Inflation Reduction Act to have knock on effect on R&D, say biotech experts
Discussions surrounding the Inflation Reduction Act (IRA) are heating up as the 2026 effect date gets closer. Speakers at the …
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them …
Merck plans €300m investment at new German research centre
Merck KGaA (Merck) has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at …
Mundipharma to acquire rezafungin assets from Cidara Therapeutics
Mundipharma has signed an agreement to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics, …